Show items per page
Elements: 4
Page 1 on 1
 TitleAuthors / EditorsDate
add to browser selection
Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study Pagani, M; De Carli, F; Morbelli, S; Öberg, J; ... Nobili, F 2015
add to browser selection
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers Ashton, N J; Leuzy, A; Karikari, T K; Mattsson-Carlgren, N; ... Hansson, O 2021
add to browser selection
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework Leuzy, A; Ashton, N J; Mattsson-Carlgren, N; Dodich, Alessandra; ... Hansson, O 2021
add to browser selection
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework Wolters, E E; Dodich, Alessandra; Boccardi, M; Corre, Julie; ... Ossenkoppele, R 2021